ArriVent BioPharma, Inc. announced initial Phase 1 results for ARR-217 (MRG007), a cadherin-17-targeting antibody-drug conjugate developed in partnership with Lepu Biopharma Co., Ltd. The data, ...
Total revenue increased 7% to a record $11.0M from $10.2M in the same prior year period. During 2026, the Company has reduced ...
ArriVent BioPharma (NASDAQ:AVBP) delivered early oncology updates with initial Phase 1 results for ARR-217, an investigational antibody-drug conjugate targeting cadherin-17 (CDH17). The candidate, ...
These leaders in cybersecurity, data analytics, and servers are benefiting from growth in AI spending.
AI selloff nears a bottom as SMH rotates into financials and software. Click for a look at the tech sector and its key ...
2dOpinion
Anthropic IPO Watch, SpaceX’s Soaring Compute Pricing, Wall Street’s Takes on CoreWeave vs. Nebius
We open with four things to look for in the Anthropic IPO filing, which could be public next week. Plus, we cover a bank note ...
ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR PRC) (“ARMOUR” or the “Company”) today announced the Company's unaudited Q3 results and September 30, 2026 financial position. Q3 2026 Results ...
The investment thesis hinges on MNDY's ability to scale operating expenses down to 75% of revenue by 2031, not just AI credit ...
The quasi-revenue numbers for OpenAI that got wide circulation last week were off— way off. Instead of $70 billion in annualized revenue, as we and others reported, OpenAI is generating closer to $50 ...
In addition, it’s important that synergies are measurable. According to the PwC deals survey, 62% of successful acquirers ...
Remibrutinib (Novartis), an oral Bruton tyrosine kinase (BTK) inhibitor, reduced annualized relapse rate (ARR) vs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results